Korean Journal of Pain最新文献

Background: Histone deacetylase 6 (HDAC6), belonging to class IIb of histone deacetylases, regulates the acetylation of the cytoplasmic protein α-tubulin. The overexpression of HDAC6 is linked to the development of tumors, and inhibiting HDAC6 is known to trigger apoptosis in multiple myeloma cells. In addition to its application in cancer treatment, bortezomib, a proteasome inhibitor, is widely used in managing multiple myeloma and has shown effectiveness in patients with both newly diagnosed and relapsed disease. However, the treatment regimen may be delayed or discontinued due to the risk of peripheral neuropathy, a significant non-hematologic side effect.

Methods: Animal models of peripheral neuropathy induced by various anti-cancer drugs were established, confirming the potential of HDAC6 inhibitors as a treatment for this condition. Six- to eight-week-old male Sprague Dawley rats were utilized to create these models. Mechanical allodynia and electron microscopy served as indicators of peripheral neuropathy. The HDAC6 inhibitor CKD-011 was administered at doses of 5, 10, 20, and 40 mg/kg.

Results: In an animal model of bortezomib-induced peripheral neuropathy, CKD-011, an HDAC6 inhibitor, effectively ameliorated peripheral neuropathy. Similarly, CKD-011 administration demonstrated recovery from peripheral neuropathy in models induced with oxaliplatin, paclitaxel, and cisplatin.

Conclusions: These findings suggest that HDAC6 inhibitors have the potential to mitigate peripheral neuropathy induced by chemotherapeutic agents.

Background: Diabetic pain patients have increased pain at night. Exosomes can relieve neuropathic pain. This study aimed to investigate the efficacy of exosome administration at different time points in relieving diabetic neuropathic pain (DNP) in rats.

Methods: M2 macrophages from bone marrow were induced in mice and exosomes were extracted. A diabetic rat model was induced using streptozotocin, with the mechanical withdrawal threshold (MWT) of the rats being measured at ≤ 80% of the basal value after 14 days, indicating successful construction of the DNP rat model. Exosomes were administered on three consecutive days at ZT0 (zeitgeber time) and ZT12. Parameters including blood glucose levels, body weight, MWT, and thermal withdrawal latency (TWL) were assessed in the rats. The lumbar spinal cord of rats was examined on days 21 and 28 to measure inflammatory factors and observe the expression of M1 and M2 microglia. Furthermore, microglia were exposed to lipopolysaccharide (LPS) and LPS + exosomes in a controlled in vitro setting to assess alterations in microglia phenotype involving the NF-kB p65 and IKBα inflammatory signaling pathways.

Results: The findings revealed that administration of exosomes during the rat resting period at ZT12 resulted in increased MWT and TWL, as well as a shift in microglia polarization towards the M2 phenotype. In vitro analysis indicated that exosomes influenced microglia polarization and suppressed the phosphorylation of NF-kB p65 and IKBα.

Conclusions: Temporal therapy with exosomes effectively reduces pain in DNP rats by polarizing microglia and affecting NF-kB p65 and IKBα signaling pathways.

Background: Evidence indicates that central sensitization (CS) plays a role in subacromial impingement syndrome (SIS). Reduced treatment response has been associated with pretreatment pain sensitization features, such as CSrelated symptoms.

Methods: Patients who received subacromial steroid injection were evaluated before the injection, at the first and third months. CS-related symptoms were investigated through the central sensitization inventory (CSI), and pain hypersensitivity was investigated by pressure pain threshold (PPT). Patients were evaluated using the visual analog scale (VAS), Quick Disabilities of the Arm, Shoulder, and Hand, Hospital Anxiety and Depression Scale, and Short Form-36.

Results: With the injection, all participants had a significant reduction in shoulder pain (P < 0.05). In all follow-ups, VAS values did not differ significantly between the groups, and patients with CSI ≥ 40 had higher levels of disability, anxiety, depression, and worse quality of life before treatment (P < 0.05). Post-injection disability decreased significantly in the CS group and reached similar levels in both groups at the third month (P > 0.05). Although both groups' PPT values were comparable pre-treatment and at the third month, the CS group's affected shoulder showed a notable PPT decline at the first month (P < 0.05).

Conclusions: Pre-treatment CS-related symptoms had no effect on SIS patients' responsiveness to steroid injections.

Background: Pain impacts quality of life (QoL) in Parkinson's disease (PD) patients, yet it is often overlooked. This study aims to comprehensively evaluate pain in PD, particularly focusing on differences between neuropathic pain (NP) and other types.

Methods: We conducted a cross-sectional study involving PD patients, assessing the prevalence and characteristics of pain. Various scales were employed to evaluate anxiety, depression, and QoL. We investigated associations between pain, demographic, and clinical variables to determine predictors and pain-related factors. Additionally, factors related to NP were explored.

Results: During the study period, a total of 109 patients were examined. Sixteen patients were excluded due to various reasons. The final analysis included 93 patients (34 females and 59 males). Pain was reported by 80.6% of PD patients, with no significant demographic or clinical differences between those with and without pain. However, longer disease duration predicted NP, and musculoskeletal pain was more prevalent in females. Anxiety was common in patients with central parkinsonian pain (CPP). Patients taking amantadine reported less radicular/ neuropathic pain (RNP), suggesting a therapeutic role.

Conclusions: Our findings underscore the high prevalence of pain in PD and its impact on QoL. NP appears to be associated with disease progression, while sex-specific differences highlight the need for personalized pain management strategies. The association between anxiety and CPP emphasizes the importance of addressing psychological factors in PD pain management. Further research on amantadine's benefits in reducing RNP is warranted, emphasizing the importance of tailored pain management strategies for PD patients.

Background: Spinal cord stimulators (SCSs) are used to reduce pain and improve quality of life in patients with complex regional pain syndrome (CRPS). However, many patients opt for device removal after SCS implantation due to diminished effect or complications. There is limited research on the actual duration of SCS use in CRPS patients, and no nationwide population-based studies exist. This study aimed to estimate the real-world duration of SCS use in CRPS patients and examine the influencing factors on the duration of SCS use by analyzing the National Healthcare Insurance Database.

Methods: Adult patients (age ≥ 18) with CRPS who underwent permanent SCS implantation between 2014 and 2021 were included. The authors analyzed the median duration of SCS implantation and evaluated the impacts of age, sex, hospital type, and insurance type.

Results: Of 408 potential patients, 373 patients were included. The median duration of SCS use was 4.4 (95% confidence interval [CI]: 4.0-4.8) years. Male patients retained SCSs longer than female patients (4.7 vs . 4.0 years, P = 0.014), and veterans' healthcare beneficiaries showed the longest duration of SCS use (median 6.9 [95% CI: 4.6-7.8] years). Age and hospital type did not affect the duration of SCS use (P = 0.381 and P = 0.122, respectively).

Conclusions: The median SCS use duration in CRPS patients was 4.4 years. Considering the high cost and invasiveness of SCS, patients should be informed about the expected duration of SCS use, alongside potential risks and benefits.